Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2008 Apr 14;6(5):575–583. doi: 10.1016/j.cgh.2008.02.035

Table 4.

Relative risk of EVR as a function of serum OAS fold-change by treatment day adjusted for race.

Treatment Day Relative Risk (95% CI) p-value
1 1.04 (1.00, 1.07) 0.047
2 1.04 (0.99, 1.09) 0.12
3 1.07 (1.02, 1.12) 0.005
7 1.06 (1.02, 1.09) 0.001
14 1.04 (1.00, 1.08) 0.037
28 1.02 (0.98, 1.06) 0.33
56 1.01 (0.97, 1.05) 0.68
84 1.02 (0.996, 1.04) 0.11
a

For every fold-change increase in serum 2,5-OAS level, EVR increased by 1-7%